newsfilter
← Earnings
Earnings Releases·

Arcus Biosciences — Third Quarter 2026 Earnings Summary

Arcus Biosciences reported third-quarter 2026 financial results showing $9 million in revenue and a net loss of $128 million, while maintaining $694 million in cash and marketable securities. The company highlighted robust clinical data for its lead candidate casdatifan in kidney cancer, demonstrating significant progression-free and overall survival benefits across multiple treatment lines. Enrollment in the Phase 3 PEAK-1 study is expected to conclude within two to three months, with the Phase 3 PEAK-20 study scheduled to begin by the end of 2026. Additionally, an interim analysis for the Phase 3 PRISM-1 trial of quemliclustat in pancreatic cancer is planned for the fourth quarter of 2026.

Company
ARCUS BIOSCIENCES INC
Sector
Healthcare
Industry
Biotechnology